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Abstract Adenosine metabolism and transport were eval-
uated in the isolated perfused mouse heart and compared
with the well-established model of isolated perfused guinea
pig heart. Coronary venous release of adenosine under
well-oxygenated conditions in the mouse exceeds that in
the guinea pig threefold when related to tissue mass. Total
myocardial adenosine production rate under this condition
was approximately 2 nmol/min per gramme and similar in
both species. Coronary resistance vessels of mice are highly
sensitive to exogenous adenosine, and the threshold for
adenosine-induced vasodilation is approximately 30 nmol/l.
Adenosine membrane transport was largely insensitive to
nitrobenzyl-thioinosine (NBTI) in mouse heart, which is in
contrast to guinea pig and several other species. This
indicates the dominance of NBTI-insensitive transporters in
mouse heart. For future studies, the assessment of cytosolic
and extracellular adenosine metabolism and its relationship
with coronary flow will require the use of more effective
membrane transport blockers.
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Introduction
The various roles of the purine adenosine for heart function
have been described in detail [1–8]. The observed effects
are mediated via activation of cell surface receptors, which
are linked to various signal transduction pathways [9, 10].
Many of the regulatory functions of adenosine have been
assessed by classical blocking experiments of adenosine
receptors or the use of receptor agonists. More recently,
genetic knock-out and overexpression models have been
developed, which permit an alternative approach to the
evaluation of individual metabolic or signal transduction
pathways (e.g., [11–15]).
Adenosine metabolism has been assessed in great detail
by our group, using the model of the isolated, perfused
guinea pig heart [16, 17]. The experimental results permitted
the development of a mathematical model of cardiac
adenosine metabolism and transport [18], which has been
proven to have predictive value for the design of consecutive
studies on adenosine metabolism [19]. Unfortunately, such
detailed data are missing for the mouse heart. Thus,
interpretation of adenosine release and function determined
in mouse heart [20, 21] has, so far, been restricted to the
analysis of relative changes. So long as a comprehensive
quantitative data set is lacking for mouse heart, the results of
experiments of knock-out and overexpression models should
be interpreted with great caution.
The present report pinpoints potential differences in
metabolism and transport of adenosine between mouse and
guinea pig heart. The goal was to provide a base for detailed
planning of future experiments aiming to provide a compre-
hensive data set describing cytosolic and extracellular
adenosine metabolism in quantitative terms. Such a data set
might then permit calculation of adenosine concentrations at
cell surface receptors as well as transmembranous concen-
tration gradients in mouse myocardium.
Materials and methods
Hearts were taken from mice anaesthetised with urethane
(1.5 mg/kg i.p.). Under a dissection microscope (magnifica-
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e-mail: Andreas.Deussen@tu-dresden.detion ×15) the ascending aorta was cannulated with stainless
steel tubing (1 mm o.d.) in a retrograde direction. The aortic
cannula was then fixed to a perfusion line providing a
modified Krebs buffer [containing (mM): 119 NaCl, 4.56
KCl, 1.2 MgSO4 1.18 KH2PO4, 24.9 NaHCO3,8 . 2 7
glucose, 2.0 pyruvate, 0.65 EDTA and 3.0 CaCl2] bubbled
through with carbogen (95% O2 and 5% CO2 at ambient
pressure) and kept at 37 °C [16]. Next, a small polyethylene
balloon connected to a thin polyethylene catheter (0.96 mm
o.d.) was advanced into the left ventricle via the left atrium
for measurement of isovolumic pressure development. A
thin polyethylene catheter was advanced into the right
ventricle for collection of the coronary venous effluent
perfusate. Two silver electrodes were fixed to the atria for
pacing at 500 bpm. The perfusion pressure was set to
85 mmHg and kept constant during the entire experiment.
Coronary flow was measured with a flow probe (diameter
1 mm, Altron Medical Electronics, Fuerstenfeldbruck,
Germany) connected to a flowmeter (Transonic Systems,
Ithaca, USA) inserted into the perfusion line approximately
2 cm above the aortic cannula. Just below the flow probe
perfusion pressure was measured with a transducer (Gould,
Statham, USA). The haemodynamic data were continuously
monitored via an interface on a PC, using Ponemah data
acquisition software (LDS Test and Measurement, Ismaning,
Germany). Steady state values of coronary flow were
reached after approximately 20 min (Figure 1). Initially
elevated flow was most likely due to ischaemia during
preparation. The following flow decline, together with an
acute flow rise in response to a 20 s complete flow stop,
was taken as an index of successful heart perfusion. Under
these conditions, mouse hearts typically extracted 72% of
the arterial oxygen supply.
The adenosine concentration of the coronary effluent
perfusate collected over periods of 1 min was assessed as
follows: 500 μl of effluent perfusate was run over Sep-PAK
c o l u m n sa sd e s c r i b e d[ 22] to increase the adenosine
concentration of the sample and remove salts. The column
eluate was dried and redissolved in 143 μl deionised water,
in which adenosine was converted to 1,N
6-etheno-adenosine
as described previously [23, 24]. The concentration of
etheno-adenosine was measured using established HPLC
techniques with fluorescence detection [23, 24].
The results of the experiments performed on mouse hearts
were averaged (mean ± SEM) and compared with results
from guinea pig heart experiments published before [19].
Results and discussion
Mouse hearts perfused under a constant pressure of
85 mmHg and paced at a rate of 500 bpm developed a
left ventricular systolic pressure of 81 ± 4 mmHg and a left
ventricular dP/dtmax of 3,634 ± 152 mmHg/s. Coronary
flow was 9.9 ± 0.4 ml/min per gramme and adenosine
release averaged 156 ± 13 pmol/min per gramme (n = 23).
Thus, coronary venous adenosine concentration averaged
15.7 nmol/l. When compared with guinea pig heart [19],
which displays a significantly lower heart rate (approxi-
mately 250 bpm) and has a similar left ventricular pressure
development (approx. 85 mmHg) but a lower dP/dtmax
(1,440 mmHg/s), coronary flow rate and cardiac adenosine
release rate of mouse heart are higher when related to the
same mass of myocardial tissue [19]. Because the differ-
ence in coronary venous adenosine release between both
species is considerably larger than the difference in flow
rate, mouse hearts displayed a significantly higher coronary
venous adenosine concentration than guinea pig hearts.
Generally higher concentrations of coronary venous
adenosine have been reported by others [20]. In their
experiments, however, only minor differences between
mouse, rat and guinea pig hearts were observed. Potentially,
differences in cardiac function may have contributed to this
difference. In our experiments the hearts beat at a higher
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Figure 1 Typical registration of
coronary flow (upper panel) and
myocardial contractility (lower
panel). The registration starts at
the time point of reperfusion.
Following a reperfusion of
30 min, a 20 s complete flow
stop is induced to challenge
coronary vessel dilation, which
permits a flow rise approxi-
mately 3.8-fold above control.
Infusion of adenosine at con-
centrations of 80 nmol/l and
200 nmol/l results in profound
increases of coronary flow,
which are well reversible upon
discontinuation of the infusion
664 Purinergic Signalling (2006) 2: 663–668rate, but diastolic pressure was adjusted to result in lower
pressure development. This experimental feature was
adjusted in order not to exceed coronary perfusion pressure
by left ventricular systolic pressure, which may have
resulted in myocardial hypoperfusion.
Adenosine produced in the myocardium is catabolised
either by phosphorylation to 5′-AMP via cytosolic adenosine
kinase or by deamination to inosine via adenosine deami-
nase. Recently, Headrick and co-workers [20] have provided
experimental evidence that in mouse heart the adenosine
flux via the kinase pathway exceeds that via the deaminase
pathway under control conditions. In addition to a cytosolic
location, adenosine deaminase has been described as being
associated with the membrane fraction in rabbit heart [25],
and an isoform is found in blood plasma [26]. However, the
latter aspect is not important for the scope of studies using
buffer perfused hearts. A potential influence of adenosine
deaminase activity bound to the outer leaflet of plasma
membrane to global adenosine production of the mouse
heart must remain open at present due to missing data.
We estimated the global mouse heart adenosine produc-
tion rate by applying iodotubericidine (ITU, 10 μM), a
powerful blocker of adenosine kinase, and erythro-9-
hydroxy-adenine (EHNA, 5 μM), a powerful blocker of
adenosine deaminase. In response to the combined infusion
of both inhibitors the coronary venous adenosine release was
severely augmented by 841% (Figure 2) and coronary flow
increased threefold. Preliminary experiments showed that
this flow increase induced by EHNA and ITU was
diminished to approximately 40% in the presence of the
A2A-receptor antagonist ZM241385. In contrast, infusion of
the A1-receptor antagonist (8-cyclopentyl-1-1,3-dipropyl-
xanthine, DPCPX) did not blunt the flow response. Thus,
the response was mediated by A2A-adenosine receptors.
The results of the combined block of adenosine kinase
and adenosine deaminase obtained in mouse heart are
similar to those measured under equivalent conditions in
guinea pig heart [19, 20]. The release under the combined
block of adenosine kinase and adenosine deaminase may be
taken as a minimum estimate of the global cardiac adenosine
production rate. Although both competitive blockers are
highly effective in the concentrations used [19], their efficacy
probably decreases when the adenosine concentration rises.
For guinea pig myocardium we had previously measured a
coronary venous release rate of 1,744 ± 518 pmol/min per
gramme under the conditions of combined block of adenosine
kinase and adenosine deaminase. Simulation of this adeno-
sine release rate by mathematical model analysis required a
global adenosine production rate of 2,295 pmol/min per
gramme [19]. Thus, adenosine production estimated directly
from adenosine release data may be underestimated by 30%.
If this result is applied to mouse heart, a global adenosine
production rate of approximately 2,000 pmol/min per
gramme may be assumed. Thus, similar to the conclusions
reported for guinea pig heart before [19], such a high
adenosine production rate exceeds adenosine release rate
under basal well-oxygenated conditions 13-fold.
Purines are transported across membranes via transport
proteins, which permit facilitative diffusion (non-concen-
trative or equilibrative nucleoside transporters) or act as
secondary active transporters using the sodium concentra-
tion difference (concentrative nucleoside transporters) [27].
The inhibition of membrane transport for adenosine has
been suggested to be of potential beneficial function under
a multitude of pathological conditions, because the inter-
stitial adenosine concentration is increased under membrane
transport block [28]. Typically, in heart tissue, equilibrative
nucleoside transport of adenosine exists [29, 30]. Based on
the efficacy of nitrobenzyl-thioinosine (NBTI) to inhibit
membrane transport, two equilibrative transport systems
may be differentiated. The first is highly sensitive to
inhibition by NBTI (<1 μM); the second is rather
insensitive to NBTI (>1 μM). In guinea pig and rat
myocardium the effectiveness of NBTI suggests that the
highly sensitive equilibrative nucleoside transport is largely
responsible for adenosine transport [29]. Similar results
have been obtained with dipyridamole (1 μM) or draflazine
(1 μM) [19]. The inhibitory effect can be demonstrated for
net myocardial adenosine release as well as for net
adenosine uptake, reflecting the concept that adenosine
transport via this nucleoside transport is equilibrative.
Purine transport systems of mouse tissues have been
studied only very recently [30]. It may be of particular
importance that mouse heart not only exhibits mRNA for
equilibrative transport proteins but also for at least two
different concentrative nucleoside transporters. Whether the
respective transport proteins are expressed and functionally
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Figure 2 Effects of combined infusion of ITU (10 μM) and EHNA
(5 μM) and additional infusion of nitrobenzyl-thioinosine (NBTI)o n
cardiac adenosine release. Combined administration of ITU and
EHNA steeply increased adenosine release in mouse hearts (black
circles) and guinea pig hearts (open circles). Additional administration
of NBTI (10 μM in mouse, 1 μM in guinea pig) only decreased
adenosine release in guinea pig heart
Purinergic Signalling (2006) 2: 663–668 665active has not been determined to date. It should be noted
that NBTI-sensitive binding sites in mouse heart ventricular
tissue were shown to be lower, by a factor of 4, than in
guinea pig heart ventricle. The dissociation constant for
NBTI binding in mouse myocardium was considerably
lower than in guinea pig myocardium [31]. This suggests
fewer NBTI-sensitive membrane transporters with a lower
affinity for NBTI in mouse myocardium.
The efficacy of NBTI to block adenosine membrane
transport was studied in our mouse heart experiments. The
cytosolic adenosine concentration was raised by simulta-
neous application of the blockers for adenosine kinase and
adenosine deaminase, iodotubercidine and EHNA, respec-
tively. Under this condition adenosine release rate was
largely elevated, as pointed out above. Co-infusion of NBTI
(10 μM) did not significantly alter this elevated adenosine
release. This result is in contrast to that obtained in guinea
pig hearts, in which a concentration of 1 μM was highly
effective to block adenosine release under this condition
(Figure 2). It indicates that membrane transport differs
remarkably in mouse heart as compared to guinea pig heart
and rat heart. In additional experiments using 100 μM
NBTI coronary perfusion pressure was severely increased,
which precluded a meaningful interpretation of adenosine
release, which was decreased under this condition. Whether
NBTI sensitivity of mouse equilibrative nucleoside trans-
port proteins differs from that of the other species, or
whether concentrative nucleoside transport proteins play an
additional role in mouse heart, remains to be determined.
The adenosine concentration in the coronary effluent
perfusate of mouse heart averaged 15.7 nmol/l under well-
oxygenated control conditions. Headrick and associates
[20] have reported a notably higher concentration of
57 ± 14 nM. The effects of A2A-receptor antagonists
on baseline coronary flow of mouse heart have been
reported previously. Those authors reported a decrease in
coronary flow of 9% in wild type mice [32]) and of even
25% in an A3-receptor knock-out mouse model [33].
Unfortunately, no measurements of adenosine release were
reported in those studies. It is thus not possible to relate
these flow effects to the available release data. However,
the data suggest that adenosine may regulate coronary flow
of mouse heart under well-oxygenated conditions.
In a first set of experiments we have addressed the
apparent mouse coronary vessel responsiveness for adeno-
sine (Figure 3). Adenosine, in a dose-dependent fashion,
increased coronary flow. At the highest concentrations used
(0.8 μM) coronary flow increased threefold, which shows
that adenosine is a powerful vasodilator of mouse coronary
vessels. Threshold concentration for flow increase was be-
tween 20 nmol/l and 40 nmol/l. This concentration range is
slightly higher than the venous adenosine concentration
determined under well-oxygenated conditions (15.7 nmol/l).
These results indicate that, if adenosine controls baseline
coronary flow of mouse heart, the net effect should be rather
small. However, because the coronary effluent adenosine
concentration is only slightly below the adenosine concentra-
tion necessary to evoke a threshold coronary flow increase, it
appears possible that minor increases of the adenosine
production rate are effective to drive the adenosine concen-
tration into the vasodilatory range. While the data from
Talukder and co-workers suggest a role of adenosine for
mouse heart coronary flow regulation under control physio-
logical conditions (isolated heart), data from Tune and co-
workers [34], obtained in the dog heart in situ, indicate that
adenosine is unimportant for the control of resting coronary
blood flow. Moreover, this group has addressed the potential
role of adenosine under a wide variety of physiological
(exercise, [33]) and pathophysiological conditions (hypoxia)
[35]. Only under conditions of hypoxia did these authors
report evidence of a role for adenosine in coronary flow
regulation. These data are, however, are in conflict with data
reported by Duncker and co-workers for pig heart [36], who
found evidence of control of coronary oxygen extraction by
adenosine under baseline physiological conditions. Further-
more, they reported evidence of parallel, rather than
redundant, flow control mechanisms involving adenosine,
NO, and KATP channels [37]. While species differences may
exist, it seems of importance to clarify whether myocardial
oxygen extraction is controlled by adenosine in mouse heart.
Such experiments should include measurements of the
adenosine concentration, because pharmacological block of
the adenosine receptors may result in an increase in the
adenosine production rate and, consecutively, of the intersti-
tial adenosine concentration, which may reduce the efficacy
of the receptor blockade.
Following detailed experimentation on guinea pig heart
and consecutive mathematical model analysis we hypothe-
sised that the adenosine concentration gradient falls from
extracellular to cytosolic under well-oxygenated conditions
[19]). The model analysis also suggested that ecto-50-
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Figure 3 Concentration–effect relationship for exogenous adenosine
and coronary flow of mouse heart. Data from five experiments
indicated by different symbols are shown
666 Purinergic Signalling (2006) 2: 663–668nucleotidase (CD73) was of great relevance for establishing
this concentration gradient. Meanwhile, Koszalka and co-
workers [15] created a knock-out mouse for CD73. They
reported that coronary flow rate of CD73 −/− hearts under
well-oxygenated conditions was significantly (−14%) lower
than that of wild type hearts. This result indicates that
membrane transport of adenosine was ineffective in adjusting
for the decreased extracellular adenosine production rate by
permitting increased cellular efflux of adenosine following
the reduction of interstitial adenosine concentration. In order
to clarify this concept it will be necessary to develop
protocols that permit the blocking of membrane transport
of mouse heart effectively.
In conclusion, we have started to assess adenosine
metabolism and transport of mouse heart. With respect to
global adenosine production rates, mice hearts are similar to
guinea pig hearts. However, membrane transport of
adenosine largely differs between both species. The
classical inhibitor NBTI, which is highly effective in
various species, does not inhibit membrane transport of
adenosine in mouse heart effectively. These results might
be attributed to insensitivity of the transport protein to
NBTI due to a different amino acid sequence. Another
possibility is that entirely different transporters (e.g.,
concentrative transport proteins) control adenosine mem-
brane transport in the mouse heart. This question remains to
be clarified in the future. Finally, mouse heart exhibits high
sensitivity to adenosine with respect to coronary flow
regulation. Experiments are in progress to test whether this
sensitivity is of importance for flow control or oxygen
extraction in mouse heart under physiological and patho-
physiological conditions.
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